Surge as Phase 1 Ebola Vaccine Begins in Canada

TLDR

1. Moderna starts Phase 1 human testing of its Bundibugyo Ebola vaccine in Canada.
2. The trial will assess safety and immune response in about 80 healthy adults.
3. CEPI commits up to $50 million to support development and clinical trial supply.
4. No approved vaccine currently protects people against Bundibugyo Ebola disease.
5. Moderna pledges at least 500,000 doses for affected lower-income countries.

Moderna (MRNA) rose 4.37% to $57.55 after launching human testing for its Bundibugyo Ebola vaccine candidate in Canada. The company vaccinated the first participants after Health Canada authorized the Phase 1 study. The trial advances a vaccine program targeting an Ebola strain without an approved preventive option.

Moderna, Inc., MRNA

Moderna Begins First Human Trial for mRNA-1469

Moderna started the study at three Canadian sites using its mRNA-1469 vaccine candidate. Researchers will assess safety, tolerability, and immune responses among healthy adults. The trial plans to enroll about 80 participants during the first stage.

The company built mRNA-1469 on the same messenger RNA platform used for its COVID-19 vaccines. Moderna also applied knowledge from earlier research involving filoviruses and related Ebola strains. That background helped the company move the candidate from laboratory work into clinical testing.

The study marks the first human evaluation of Moderna’s vaccine against Bundibugyo ebolavirus disease. No licensed vaccine currently protects people from illness caused by this specific virus. Existing Ebola vaccines mainly target Zaire ebolavirus, which differs from the active outbreak strain.

CEPI Funding Supports Rapid Vaccine Development

CEPI committed up to $50 million for preclinical work and the Phase 1 study. The partnership also funds production of extra clinical doses during early development. This structure could shorten preparation time for larger studies after favorable initial results.

Moderna plans to use Phase 1 findings to guide possible Phase 2 and Phase 3 trials. The company can expand testing quickly because manufacturing work will continue alongside clinical research. However, later development will still depend on safety and immune response data.

The agreement also includes supply commitments for countries facing limited vaccine access. Moderna will reserve at least 500,000 doses for lower-income and middle-income markets. The company plans to offer those doses under access pricing after any future approval.

Congo Outbreak Increases Demand for New Protection

Bundibugyo ebolavirus has driven the active outbreak in the Democratic Republic of the Congo. Health authorities have reported more than 3,000 confirmed cases and over 1,400 deaths. Those figures place the outbreak among the largest filovirus emergencies recorded worldwide.

The World Health Organization declared a Public Health Emergency of International Concern. Africa CDC also declared a Public Health Emergency of Continental Security. Both decisions reflect the outbreak’s size, speed, and growing regional risk.

The Canadian trial now gives health agencies another potential tool against the outbreak strain. Moderna must still complete clinical testing before regulators can consider any approval. Meanwhile, the program strengthens the company’s infectious disease pipeline and expands its mRNA vaccine research.